Table 1 Breast cancer patient characteristics (categorial variables)
Parameters | All BC patients analyzed in this study | HER2-positive patients | TNBC patients | All BC patients in GeparSixto trial | p value* | |
|---|---|---|---|---|---|---|
Total | 435 (100.0%) | 211 (100.0%) | 244 (100.0%) | 588 (100.0%) | ||
Subtype | HER2-positive patients | 211 (48.5%) | Subgroups of all BC patients analyzed in this study | 273 (46.4%) | 0.0909 | |
TNBC patients | 224 (51.5%) | 315 (53.6%) | ||||
Age | < 50 | 249 (57.2%) | 120 (56.9%) | 129 (57.6%) | 341 (58.0%) | 0.5684 |
≥ 50 | 186 (42.8%) | 91 (43.1%) | 95 (42.4%) | 247 (42.0%) | ||
Lymph node metastasis | N0 | 240 (56.1%) | 106 (50.7%) | 134 (61.2%) | 338 (58.7%) | 0.0333 |
N+ | 188 (43.9%) | 103 (49.3%) | 85 (38.8%) | 238 (41.3%) | ||
Missing | 7 | 2 | 5 | 12 | ||
Tumor size | T1–2 | 365 (84.3%) | 167 (79.9%) | 198 (88.4%) | 499 (85.2%) | 0.3570 |
T3–4 | 68 (15.7%) | 42 (20.1%) | 26 (11.6%) | 87 (14.8%) | ||
Missing | 2 | 2 | 0 | 2 | ||
Grading | G1–2 | 151 (34.7%) | 93 (44.1%) | 58 (25.9%) | 207 (35.2%) | 0.6944 |
G3 | 284 (65.3%) | 118 (55.9%) | 166 (74.1%) | 381 (64.8%) | ||
Lymphocyte predominant breast cancer | pos. | 108 (25.1%) | 44 (21.4%) | 64 (28.6%) | 142 (24.4%) | 0.5825 |
neg. | 322 (74.9%) | 162 (78.6%) | 160 (71.4%) | 439 (75.6%) | ||
Missing | 5 | 5 | 0 | 7 | ||
Therapy arm | PM | 222 (51.0%) | 109 (51.7%) | 113 (50.4%) | 293 (49.8%) | 0.3478 |
PMCb | 213 (49.0%) | 102 (48.3%) | 111 (49.6%) | 295 (50.2%) | ||
Pathological complete response (pCR) | Yes | 223 (51.3%) | 113 (53.6%) | 110 (49.1%) | 296 (50.3%) | 0.4540 |
No | 212 (48.7%) | 98 (46.4%) | 114 (50.9%) | 292 (49.7%) | ||